The proposed bacteria-promoted nanocatalytic tumor immunity activation is expected to be a clinically promising therapeutic modality for cancer integrated immunotherapy without using any highly toxic chemodrug, especially for intractable CRC in which the abundant colonization of bacteria such as Fn in tumor tissue causes drug resistance and immunosuppression of tumor cells. The gene discussed is FN1; the disease is colorectal carcinoma.